Clinical Trial Update: Open Label, Phase I ZD6474 Head and Neck Cancer Study [Phase 1]

View source ↗

Summary

Open-label Phase I study of ZD6474 (vandetanib) in head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Caprelsa (vandetanib)

Snippet

Sponsor: Sanofi | Conditions: Head and Neck Cancer | Phase 1 | Status: COMPLETED